Interaction of 16beta-hydroxydehydroepiandrosterone with renal mineralocorticoid receptors.
A previously unidentified mineralocorticoid, 16beta-hydroxydehydroepiandrosterone (16beta OH-DHEA) has recently been isolated from urine extracts of patients with low-renin hypertension and reported to possess one-fortieth the mineralocorticoid potency of aldosterone by bioassay. However, using a radioreceptor assay, we demonstrate the affinity of 16beta-OH-DHEA for renal 3H-aldosterone receptors to be only 0.011 per cent that of unlabeled aldosterone. 16beta-OH-DHEA therefore would not be expected to possess significant mineralocorticoid properties unless its mechanism of action involves binding to a unique class of renal receptors. Until these discrepancies between bioassayable mineralocorticoid activity and affinity for mineralocorticoid receptors can be resolved, the role of 16beta-OH-DHEA in the pathogenesis of low-renin hypertension remains speculative.
D000450:Aldosterone; D000818:Animals; D001667:Binding, Competitive; D003687:Dehydroepiandrosterone / Q000031:analogs & derivatives* / Q000378:metabolism; D006973:Hypertension / Q000209:etiology; D007668:Kidney; D008297:Male; D008901:Mineralocorticoids / Q000378:metabolism; D011869:Radioligand Assay; D051381:Rats; D011987:Receptors, Steroid / Q000378:metabolism*; D014316:Tritium
D008901:Mineralocorticoids; D011987:Receptors, Steroid; D014316:Tritium; D003687:Dehydroepiandrosterone; D000450:Aldosterone